MI-ONCOSEQ is study that enrolls patients with metastatic cancer or cancer that is resistant to treatment, to undergo an "integrative sequencing approach" to provide a comprehensive landscape of the genetic alterations in individual tumor specimens for the purpose of identifying informative and/or actionable mutations. Furthermore, it can identify certain germline (inherited) alterations that may also be relevant to patients and their families. For patients with advanced, metastatic disease, participating in MI-ONCOSEQ may help guide the future treatment of their cancer.

To learn more about how to participate in the study, please discuss with your treating physician/oncologist first and have them contact our study coordinators at MiOncoSeq-Admin@med.umich.edu.